Zoetis Belgium S.a

Abbvie Inc.

Abbott Laboratories Corporation

Susan E Lacy

Emma Fung

Ravi Chari

Meha Chhaya

Charles W Hutchins

Mary Leddy

Eve H Barlow

Diane M Lang

Jeffrey A Barbon

Shankar Kumar

Richard W Dixon

Paul Robert Hinton

Michael Roguska

Lorenzo Benatuil

Edward B Reilly

Jonathan P Belk

Jacqueline G Bixby

Renee Miller

Sarah J Heighton

The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.

Caninized anti-NGF antibodies and their use

Anti-NGF antibodies and their use

The disclosure provides binding proteins that specifically bind to IL-1&#x3b1; and IL-1&#x3b2;. These binding proteins can be organized into DVD-Igs. These proteins can be used to modulate the activity of IL-1&#x3b1; and/or IL-1&#x3b2; and can be used for the treatment immunological diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, multiple sclerosis, and other autoimmune diseases. In addition, their uses in the amelioration and/or treatment of pain in an individual suffering from a disease or disorder associated with IL-1 accumulation.

IL-1 binding proteins

The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

IL-12/p40 binding proteins

Growing community of inventors

Westborough, MA, United States of America

Susan E Lacy